Morning Analysis on Pharma Equities -- Teva Pharma Industries, Hospira, Depomed, TherapeuticsMD, and Pernix Therapeutics Holdings

LONDON, May 8, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Hospira Inc. (NYSE: HSP), Depomed Inc. (NASDAQ: DEPO), TherapeuticsMD Inc. (NYSE MKT: TXMD), and Pernix Therapeutics Holdings Inc. (NASDAQ:  PTX). Free research report on Teva Pharma Industries can be accessed http://get.Investor-Edge.com/pdf/?c=Teva%20Pharma%20Industries&d=08-May-2015&s=TEVA. On Thursday, May 07, 2015, the NASDAQ Composite ended at 4,945.54, up 0.53%, the Dow Jones Industrial Average advanced 0.46%, to finish the day at 17,924.06, and the S&P 500 closed at 2,088.00, up 0.38%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 834.99, up 0.47%, with the index also advancing 3.49% in the previous three months. Register for your complimentary reports at the links given below.  

On Thursday, shares in Teva Pharmaceutical Industries Ltd fluctuated between $59.76 and $60.57 before ending the session 0.18% lower at $60.04. The stock reported a trading volume of 4.25 million shares, below its three months average volume of 5.77 million shares. Although, Teva Pharmaceutical Industries Ltd's shares have lost 3.05% in the previous three trading sessions, it has advanced 4.24% in the last three months and 4.40% on YTD basis. The company is trading above its 200-day moving average of $56.68. Moreover, shares of Teva Pharmaceutical Industries Ltd have a Relative Strength Index (RSI) of 40.96. Sign up and read the free notes on TEVA at:

http://get.Investor-Edge.com/pdf/?c=Teva%20Pharma%20Industries&d=08-May-2015&s=TEVA

Hospira Inc.'s stock edged 0.07% higher, to close the day at $87.75. The stock recorded a trading volume of 0.98 million shares, much below its three months average volume of 2.65 million shares. The stock oscillated between $87.56 and $87.76 during the session. Over the last three trading sessions and over the past three months, Hospira Inc.'s shares have gained 0.02% and 0.37%, respectively. Furthermore, the stock has surged 43.27% since the start of this year. The company is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $87.68 is above its 200-day moving average of $66.34. Additionally, Hospira Inc. traded at a PE ratio of 36.84 and has an RSI of 59.26. The complimentary notes on HSP can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Hospira&d=08-May-2015&s=HSP

On Thursday, shares in Depomed Inc. recorded a trading volume of 1.07 million shares, lower than its three months average volume of 1.56 million shares. The stock ended the day at $23.64, which was 0.25% below its previous day's closing of $23.70, and registered an intraday range of $23.14 and $23.83. Shares of the company traded at a PE ratio of 12.74. Depomed Inc.'s shares have advanced 2.07% in the last one month, 32.96% in the previous three months and 46.74% on YTD basis. The company is trading above its 200-day moving average of $17.63. Furthermore, shares of Depomed Inc. have an RSI of 44.00. Register for free on Investor-Edge and access the latest research on DEPO at:

http://get.Investor-Edge.com/pdf/?c=Depomed&d=08-May-2015&s=DEPO

TherapeuticsMD Inc.'s stock gained 0.99%, to close Thursday's session at $6.10, after oscillating between $6.00 and $6.11. The stock recorded a trading volume of 0.75 million shares, below its three months average volume of 1.44 million shares. Over the last three months and since the beginning of 2015, TherapeuticsMD Inc.'s shares have surged 46.63% and 37.08%, respectively. However, the stock has declined 3.94% in the last one month. The company is trading above its 200-day moving average. The stock's 50-day moving average of $6.17 is above its 200-day moving average of $4.95. Furthermore, TherapeuticsMD Inc.'s stock has an RSI of 40.05. The complete research on TXMD is available for free at:

http://get.Investor-Edge.com/pdf/?c=TherapeuticsMD&d=08-May-2015&s=TXMD

Pernix Therapeutics Holdings Inc.'s stock finished Thursday's session 4.66% higher at $6.74. A total of 1.35 million shares were traded, which was above its three months average volume of 1.05 million shares. The stock moved between $6.59 and $6.98 during the session. Pernix Therapeutics Holdings Inc.'s shares have lost 32.40% in the last one month and 28.22% since the start of this year. However, the stock has gained 1.20% in the previous three trading sessions. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $9.54 is greater than its 200-day moving average of $8.92. Pernix Therapeutics Holdings Inc.'s stock has an RSI of 29.02. Free in depth research on PTX is available at:

http://get.Investor-Edge.com/pdf/?c=Pernix%20Therapeutics%20Holdings&d=08-May-2015&s=PTX

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.